Literature DB >> 23897307

The value of gadoxetic acid-enhanced and diffusion-weighted MRI for prediction of grading of pancreatic neuroendocrine tumors.

Kyung Mi Jang1, Seong Hyun Kim, Soon Jin Lee, Dongil Choi.   

Abstract

BACKGROUND: Parenchyma-preserving resection for the treatment of benign pancreatic neuroendocrine tumors (NETs) has been tried, and preoperative prediction of benign pancreatic NET is important. Recently, diffusion-weighted imaging (DWI) of abdomen magnetic resonance imaging (MRI) has been used to characterize benign and malignant tumors and DWI might be helpful in prediction of benign pancreatic NETs.
PURPOSE: To evaluate the value of gadoxetic acid-enhanced MRI and DWI in predicting benign pancreatic NETs for determination of parenchyma-preserving resection.
MATERIAL AND METHODS: Our ethics committee approved this study with a waiver of informed consent given its retrospective design. We searched radiology and pathology databases from November 2010 to July 2012 to identify patients who underwent surgery for pancreatic NETs (<4 cm). Twenty patients in the benign group and 14 patients in the non-benign group were included in this study. Two radiologists analyzed the morphologic features, signal intensity on MR images including DWI (b = 800), and dynamic enhancement pattern of the tumors with consensus. The tumor-to-parenchyma ratio and tumor apparent diffusion coefficients (ADCs) were quantitatively assessed.
RESULTS: The benign pancreatic NETs were more often round (7/20, 35%) or ovoid (13/20, 65%) in shape and less hypovascular on the arterial phase (3/20, 15%) than were the non-benign pancreatic NETs (1/14, 7.1% and 5/14, 35.8%; 7/14, 50% respectively; P < 0.05). Main pancreatic duct dilatation by tumors was demonstrated only in non-benign pancreatic NETs (4/14, 28.4%; P = 0.021). ADC values and ratios were significantly different between benign pancreatic NETs (mean, 1.48 × 10(-3 )mm(2)/sec, 1.11 ± 0.25, each) and non-benign pancreatic NETs (mean, 1.04 × 10(-3 )mm(2)/sec, 0.74 ± 0.13, each) (P < 0.01). Other qualitative and quantitative analyses between benign and non-benign pancreatic NETs were not significantly different (P > 0.05).
CONCLUSION: Abdominal MRI with DWI may be useful for differentiating benign pancreatic NETs from non-benign pancreatic NETs, which might be helpful for determination of parenchyma-preserving resection.

Entities:  

Keywords:  Pancreas; magnetic resonance imaging; neuroendocrine tumor

Mesh:

Substances:

Year:  2013        PMID: 23897307     DOI: 10.1177/0284185113494982

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  34 in total

1.  CT radiomics may predict the grade of pancreatic neuroendocrine tumors: a multicenter study.

Authors:  Dongsheng Gu; Yabin Hu; Hui Ding; Jingwei Wei; Ke Chen; Hao Liu; Mengsu Zeng; Jie Tian
Journal:  Eur Radiol       Date:  2019-06-21       Impact factor: 5.315

2.  Is the combination of MR and CT findings useful in determining the tumor grade of pancreatic neuroendocrine tumors?

Authors:  Fumihito Toshima; Dai Inoue; Takahiro Komori; Kotaro Yoshida; Norihide Yoneda; Tetsuya Minami; Osamu Matsui; Hiroko Ikeda; Toshifumi Gabata
Journal:  Jpn J Radiol       Date:  2017-03-03       Impact factor: 2.374

3.  Apparent diffusion coefficient as a potential marker for tumour differentiation, staging and long-term clinical outcomes in gallbladder cancer.

Authors:  Ji Hye Min; Tae Wook Kang; Dong Ik Cha; Seong Hyun Kim; Kyung Sook Shin; Jeong Eun Lee; Kee-Taek Jang; Soo Hyun Ahn
Journal:  Eur Radiol       Date:  2018-06-25       Impact factor: 5.315

4.  Hepatic neuroendocrine tumour: Apparent diffusion coefficient as a potential marker of prognosis associated with tumour grade and overall survival.

Authors:  Ji Hye Min; Tae Wook Kang; Young Kon Kim; Seong Hyun Kim; Kyung Sook Shin; Jeong Eun Lee; Sang Yun Ha; Insuk Sohn
Journal:  Eur Radiol       Date:  2018-01-24       Impact factor: 5.315

Review 5.  State-of-the-art Imaging of Pancreatic Neuroendocrine Tumors.

Authors:  Eric P Tamm; Priya Bhosale; Jeffrey H Lee; Eric M Rohren
Journal:  Surg Oncol Clin N Am       Date:  2016-04       Impact factor: 3.495

Review 6.  Prognostication and response assessment in liver and pancreatic tumors: The new imaging.

Authors:  Riccardo De Robertis; Paolo Tinazzi Martini; Emanuele Demozzi; Gino Puntel; Silvia Ortolani; Sara Cingarlini; Andrea Ruzzenente; Alfredo Guglielmi; Giampaolo Tortora; Claudio Bassi; Paolo Pederzoli; Mirko D'Onofrio
Journal:  World J Gastroenterol       Date:  2015-06-14       Impact factor: 5.742

Review 7.  Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2018-07-17       Impact factor: 4.512

Review 8.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

9.  Can histogram analysis of MR images predict aggressiveness in pancreatic neuroendocrine tumors?

Authors:  Riccardo De Robertis; Bogdan Maris; Nicolò Cardobi; Paolo Tinazzi Martini; Stefano Gobbo; Paola Capelli; Silvia Ortolani; Sara Cingarlini; Salvatore Paiella; Luca Landoni; Giovanni Butturini; Paolo Regi; Aldo Scarpa; Giampaolo Tortora; Mirko D'Onofrio
Journal:  Eur Radiol       Date:  2018-01-19       Impact factor: 5.315

10.  Can MDCT or EUS features predict the histopathological grading scheme of pancreatic neuroendocrine neoplasms?

Authors:  Hui Zhu; Lang Ying; Wei Tang; Xiujiang Yang; Bo Sun
Journal:  Radiol Med       Date:  2017-02-07       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.